Rheumatoid arthritis combo drug trial stalls after just 2 patients
NCT ID NCT05306353
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested whether adding an experimental drug called VIB4920 to standard TNF-inhibitor therapy could improve disease control in people with rheumatoid arthritis. Only 2 participants were enrolled before the study was terminated, so no meaningful conclusions can be drawn. The goal was to see if the combination could help those who don't get enough relief from TNF inhibitors alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VIB4920 (a CD40L-binding protein) plus a TNF-alpha inhibitor
What this could lead to
If it worked, this combination might offer better disease control for people with rheumatoid arthritis who don't respond well to standard TNF inhibitors.
What could go wrong
The trial was terminated early with only 2 participants, so we have very little data. It is unclear if VIB4920 is safe or effective, and the approach may not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham & Women's Hospital: Department of Medicine, Rheumatology, Immunology
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center: Division of Rheumatology and Immunology
Durham, North Carolina, 27710, United States
-
University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center
San Francisco, California, 94110, United States
-
University of Colorado School of Medicine: Division of Rheumatology
Aurora, Colorado, 80045, United States
-
University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology
Ann Arbor, Michigan, 48109, United States